HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

John J P Kastelein Selected Research

Hyperlipoproteinemia Type II (Familial Hypercholesterolemia)

1/2022Resmetirom (MGL-3196) in Patients With Heterozygous Familial Hypercholesterolemia.
1/2021Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis.
1/2021LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial.
1/2021A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia.
10/2020Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia.
9/2020Corrigendum to "Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia" J Clin Lipidol 11 (2017) 1338-1346.
1/2020Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia.
10/201920-Year Follow-up of Statins in Children with Familial Hypercholesterolemia.
1/2019Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia.
7/2018Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


John J P Kastelein Research Topics

Disease

122Cardiovascular Diseases (Cardiovascular Disease)
11/2022 - 01/2002
107Hyperlipoproteinemia Type II (Familial Hypercholesterolemia)
01/2022 - 07/2002
76Coronary Artery Disease (Coronary Atherosclerosis)
01/2021 - 05/2002
75Atherosclerosis
01/2021 - 01/2002
62Coronary Disease (Coronary Heart Disease)
01/2019 - 04/2002
40Myocardial Infarction
01/2021 - 12/2002
24Inflammation (Inflammations)
04/2022 - 12/2002
22Hypercholesterolemia
09/2020 - 10/2003
21Stroke (Strokes)
01/2019 - 04/2005
20Dyslipidemias (Dyslipidemia)
12/2020 - 10/2004
17Atherosclerotic Plaque (Atheroma)
01/2021 - 02/2006
17Hypertension (High Blood Pressure)
07/2018 - 06/2004
13Neoplasms (Cancer)
01/2019 - 09/2004
12Homozygous Familial Hypercholesterolemia
05/2022 - 03/2014
12Metabolic Syndrome (Dysmetabolic Syndrome X)
03/2013 - 04/2005
11Injection Site Reaction
09/2020 - 08/2007
11Vascular Diseases (Vascular Disease)
11/2016 - 12/2002
10Hypertriglyceridemia
01/2022 - 09/2004
10Hyperlipidemias (Hyperlipidemia)
01/2022 - 02/2002
10Type 2 Diabetes Mellitus (MODY)
05/2021 - 12/2004
10Acute Coronary Syndrome
01/2019 - 04/2005
10Diabetes Mellitus
01/2018 - 11/2005
10Carotid Artery Diseases
12/2013 - 05/2003
9Unstable Angina
01/2019 - 11/2008
8Insulin Resistance
11/2022 - 07/2007
7Hypoalphalipoproteinemias (Hypoalphalipoproteinemia)
12/2014 - 10/2002
6Body Weight (Weight, Body)
01/2020 - 05/2007
6Inborn Genetic Diseases (Disease, Hereditary)
01/2019 - 04/2005
6Heart Failure
12/2015 - 02/2007
5Pancreatitis
12/2019 - 09/2004
5Hypotension (Low Blood Pressure)
11/2016 - 04/2005
5Abdominal Obesity
07/2011 - 01/2008
4Chronic Renal Insufficiency
01/2019 - 12/2006
4Infections
01/2017 - 10/2004
4Heart Arrest (Cardiac Arrest)
04/2012 - 04/2005

Drug/Important Bio-Agent (IBA)

122Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
01/2021 - 07/2002
98LDL CholesterolIBA
11/2022 - 04/2002
91LipidsIBA
04/2022 - 10/2002
75oxidized low density lipoproteinIBA
11/2022 - 04/2002
65HDL CholesterolIBA
11/2022 - 05/2002
46CholesterolIBA
01/2022 - 01/2002
36Lipoproteins (Lipoprotein)IBA
01/2019 - 08/2002
35Atorvastatin (Lipitor)FDA Link
01/2019 - 12/2002
28Triglycerides (Triacylglycerol)IBA
01/2019 - 06/2004
28ApolipoproteinsIBA
03/2018 - 06/2003
27Apolipoproteins B (ApoB)IBA
11/2022 - 10/2003
25LDL Lipoproteins (beta Lipoproteins)IBA
01/2020 - 10/2003
24Apolipoprotein A-I (Apolipoprotein A1)IBA
01/2021 - 10/2004
24Biomarkers (Surrogate Marker)IBA
01/2016 - 12/2002
23Simvastatin (Zocor)FDA LinkGeneric
03/2013 - 07/2002
22C-Reactive ProteinIBA
01/2019 - 12/2002
19HDL LipoproteinsIBA
01/2018 - 08/2004
18Cholesterol Ester Transfer ProteinsIBA
09/2022 - 01/2003
18LDL Receptors (LDL Receptor)IBA
01/2019 - 12/2002
15Pravastatin (Pravachol)FDA LinkGeneric
10/2019 - 05/2003
12Ezetimibe (Zetia)FDA Link
01/2021 - 02/2005
12alirocumabIBA
09/2020 - 06/2014
12Rosuvastatin Calcium (Crestor)FDA Link
01/2018 - 03/2003
12Trinitrotoluene (TNT)IBA
11/2016 - 09/2006
11Proprotein Convertase 9IBA
01/2021 - 06/2014
9mipomersenIBA
01/2021 - 05/2010
9Lipoprotein Lipase (Diacylglycerol Lipase)IBA
01/2019 - 09/2004
8Glucose (Dextrose)FDA LinkGeneric
11/2022 - 06/2004
8Proteins (Proteins, Gene)FDA Link
01/2021 - 10/2003
7Pharmaceutical PreparationsIBA
01/2020 - 02/2004
7torcetrapibIBA
11/2012 - 04/2007
6EnzymesIBA
04/2022 - 06/2006
6dalcetrapibIBA
12/2014 - 05/2002
5Insulin (Novolin)FDA Link
09/2022 - 09/2009
5Lipoprotein(a)IBA
01/2022 - 06/2004
5DNA (Deoxyribonucleic Acid)IBA
08/2017 - 05/2004
5Secretory Phospholipases A2IBA
01/2014 - 04/2005
5AdiponectinIBA
01/2012 - 01/2008
5Adenosine Triphosphate (ATP)IBA
10/2011 - 10/2002
4ALN-PCSIBA
01/2021 - 01/2017
4CSL112IBA
01/2021 - 10/2016
4evolocumabIBA
10/2020 - 06/2016
4Monoclonal AntibodiesIBA
01/2020 - 06/2014
4bococizumabIBA
07/2018 - 08/2016
4CER-001IBA
01/2018 - 12/2014
4lipoprotein cholesterolIBA
11/2016 - 04/2005
4Phytosterols (Plant Sterols)IBA
12/2014 - 12/2005
4Aryldialkylphosphatase (Paraoxonase)IBA
08/2009 - 02/2005
3Eicosapentaenoic AcidIBA
04/2022 - 01/2014
3Fatty Acids (Saturated Fatty Acids)IBA
04/2022 - 01/2016
3icosabutateIBA
04/2022 - 01/2016
3Nonesterified Fatty Acids (NEFA)IBA
01/2022 - 01/2012
3BMS201038IBA
01/2021 - 03/2014
3Phospholipids (Phosphatides)FDA LinkGeneric
11/2020 - 05/2006
3CreatinineIBA
01/2019 - 12/2006
3omega-Chloroacetophenone (Mace)IBA
01/2019 - 12/2015
3varespladibIBA
01/2019 - 04/2011
3Apolipoprotein C-IIIIBA
11/2018 - 07/2015

Therapy/Procedure

94Therapeutics
09/2022 - 08/2002
10Secondary Prevention
01/2021 - 11/2005
5Resuscitation
06/2013 - 04/2005
4Drug Therapy (Chemotherapy)
01/2021 - 06/2004
4Subcutaneous Injections
01/2021 - 12/2016
3Blood Component Removal (Apheresis)
01/2021 - 10/2014
3Intravenous Infusions
01/2020 - 01/2018